AXL and renal cell carcinoma: A landmark study from Qu et al. revealed that exosomal lncARSR derived from resistant renal cell carcinoma (RCC) cells could confer sunitinib resistance to endothelial cells by functioning as a ceRNA to quench miR-34 and miR-449, thereby leading to accumulated AXL and c-MET expression.